KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia

Epigenetics

Volumn 7, Issue 3, 2012, Pages 211-215

  Shinawi, Thoraia ^a   Hill, Victoria ^a   Dagklis, Antonis ^b   Baliakas, Panagiotis ^c   Stamatopoulos, Kostas ^c   Agathanggelou, Angleo ^a   Stankovic, Tanja ^a   Maher, Eamonn R ^a   Ghia, Paolo ^b   Latif, Farida ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Chronic lymphocytic leukemia; DNA methylation; KIBRA; Prognostic marker; RASSF genes; SWH pathway

Indexed keywords

CRB3 PROTEIN; KIBRA PROTEIN; RAS ASSOCIATION DOMAIN FAMILY 10 PROTEIN; RAS ASSOCIATION DOMAIN FAMILY 6 PROTEIN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CHRONIC LYMPHATIC LEUKEMIA; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN METHYLATION;

EID: 84858220295     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.7.3.19222     Document Type: Article

References (30)

1. Caligaris-Cappio F, Ghia P. Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 2008; 26:4497-503. PMID:18662968; http://dx.doi. org/10.1200/JCO.2007.15.4393.
2. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94:1840-7. PMID:10477712.
3. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94:1848-54. PMID:10477713.
4. Ghia P, Guida G, Stella S, Gottardi D, Geuna M, Strola G, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101:1262-9. PMID:12406914; http://dx.doi. org/10.1182/blood-2002-06-1801.
5. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348:1764-75. PMID:12724482; http://dx.doi. org/10.1056/NEJMoa023143.
6. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-6. PMID:11136261; http:// dx.doi.org/10.1056/NEJM200012283432602.
7. Rodríguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17:330-9. PMID:21386836; http://dx.doi.org/10.1038/ nm.2305.
8. Galm O, Herman JG, Baylin SB. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006; 20:1-13. PMID:16426940; http://dx.doi. org/10.1016/j.blre.2005.01.006.
9. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol 2005; 23:3877-85. PMID:15809452; http://dx.doi.org/10.1200/ JCO.2005.02.196.
10. Strathdee G, Sim A, Parker A, Oscier D, Brown R. Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL. Leukemia 2006; 20:1326-9. PMID:16688227; http://dx.doi.org/10.1038/sj.leu.2404254.
11. Rahmatpanah FB, Carstens S, Hooshmand SI, Welsh EC, Sjahputera O, Taylor KH, et al. Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenomics 2009; 1:39-61. PMID:20495622; http:// dx.doi.org/10.2217/epi.09.10.
12. Kanduri M, Cahill N, Göransson H, Enström C, Ryan F, Isaksson A, et al. Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood 2010; 115:296-305. PMID:19897574; http://dx.doi.org/10.1182/ blood-2009-07-232868.
13. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796:114-28. PMID:19344752.
14. Underhill-Day N, Hill V, Latif F. N-terminal RASSF family: RASSF7-RASSF10. Epigenetics 2011; 6:284-92. PMID:21116130; http://dx.doi.org/10.4161/ epi.6.3.14108.
15. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009; 8:42. PMID:19570220; http://dx.doi.org/10.1186/1476-4598-8-42.
16. Hill VK, Dunwell TL, Catchpoole D, Krex D, Brini AT, Griffiths M, et al. Frequent epigenetic inactivation of KIBRA, an upstream member of the Salvador/ Warts/Hippo (SWH) tumor suppressor network, is associated with specific genetic event in B-cell acute lymphocytic leukemia. Epigenetics 2011; 6:326-32. PMID:21173572; http://dx.doi.org/10.4161/ epi.6.3.14404.
17. Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, et al. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 2011; 30:978-89. PMID:20956940; http:// dx.doi.org/10.1038/onc.2010.471.
18. Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, et al. V(H) mutation status, CD38 expression level, genomic aberrations and survival in chronic lymphocytic leukemia. Blood 2002; 100:1410-6. PMID:12149225.
19. Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development 2011; 138:9-22. PMID:21138973; http://dx.doi.org/10.1242/ dev.045500.
20. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19:491-505. PMID:20951342; http://dx.doi.org/10.1016/j.devcel.2010.09.011.
21. Baumgartner R, Poernbacher I, Buser N, Hafen E, Stocker H. The WW domain protein Kibra acts upstream of Hippo in Drosophila. Dev Cell 2010; 18:309-16. PMID:20159600; http://dx.doi. org/10.1016/j.devcel.2009.12.013.
22. Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. Kibra is a regulator of the Salvador/Warts/ Hippo signaling network. Dev Cell 2010; 18:300-8. PMID:20159599; http://dx.doi.org/10.1016/j.devcel.2009.12.011.
23. Yu J, Zheng Y, Dong J, Klusza S, Deng WM, Pan D. Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell 2010; 18:288-99. PMID:20159598; http://dx.doi.org/10.1016/j.devcel.2009.12.012.
24. Chen CL, Gajewski KM, Hamaratoglu F, Bossuyt W, Sansores-Garcia L, Tao C, et al. The apical-basal cell polarity determinant Crumbs regulates Hippo signaling in Drosophila. Proc Natl Acad Sci USA 2010; 107:15810-5. PMID:20798049; http://dx.doi. org/10.1073/pnas.1004060107.
25. Ling C, Zheng Y, Yin F, Yu J, Huang J, Hong Y, et al. The apical transmembrane protein Crumbs functions as a tumor suppressor that regulates Hippo signaling by binding to Expanded. Proc Natl Acad Sci USA 2010; 107:10532-7. PMID:20498073; http://dx.doi. org/10.1073/pnas.1004279107.
26. Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci USA 2010; 107:1437-42. PMID:20080689; http://dx.doi.org/10.1073/pnas.0911427107.
27. Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci USA 2010; 107:1431-6. PMID:20080598; http://dx.doi.org/10.1073/ pnas.0911409107.
28. Zhou D, Zhang Y, Wu H, Barry E, Yin Y, Lawrence E, et al. Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proc Natl Acad Sci USA 2011; 108:1312-20. PMID:22042863; http://dx.doi.org/10.1073/ pnas.1110428108.
29. Hesson LB, Cooper WN, Latif F. The role of RASSF1A methylation in cancer. Dis Markers 2007; 23:73-87. PMID:17325427.
30. Hartmann EM, Campo E, Wright G, Lenz G, Salaverria I, Jares P, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood 2010; 116:953-61. PMID:20421449; http://dx.doi. org/10.1182/blood-2010-01-263806.